Lung Cell Protein Triggers a Dangerous Immune Response
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: Teneema Kuriakose, Ph.D., a postdoctoral research associate, and Thirumala-Devi Kanneganti, Ph.D. Immunologists have identified the protein trigger in the body’s quick-reaction innate immune system that specifically recognizes the influenza virus in infected cells and triggers their death (Photo courtesy of St. Jude Children’s Research Hospital).
A protein in the cytoplasm of lung cells helps protect against viral infection, but following invasion by the influenza virus, the same protein stimulates the immune system to overact, which can lead to inflammation or pneumonia.
Individuals infected with influenza become ill not only because of the presence of virus but also because of the inflammatory immune response triggered by reaction to the virus.
The Z-DNA binding protein 1 (ZBP1, also known as DNA-dependent activator of IFN regulatory factors) gene encodes a Z-DNA binding protein. Z-DNA formation is a dynamic process, largely controlled by the amount of supercoiling. ZBP1 recognizes DNA in the cytoplasm as an antiviral mechanism. Viral life cycles often include steps where DNA is exposed in the cytoplasm. DNA is normally contained in the nucleus of a cell, and therefore cells use proteins like ZBP1 as an indicator of a viral infection. Once ZBP1 is activated, it increases the production of antiviral cytokines such as interferon-beta (INF-beta).
Investigators at St. Jude Children's Research Hospital (Memphis, TN, USA) initially demonstrated that ZBP1-mediated sensing of the influenza A virus (IAV) proteins NP and PB1 triggered cell death and inflammatory responses.
In order to further clarify the role of ZPB1 in flu infection, they used genetic engineering techniques to create a line of mice that lacked the ZBP1 gene.
The investigators reported in the August 12, 2016, online edition of the journal Science Immunology that mice lacking ZBP1 showed an increased viral load and delayed recovery. On the other hand, these mice had decreased inflammation and less epithelial damage than control animals.
"Our discovery was totally unexpected," said senior author Dr. Thirumala-Devi Kanneganti, an immunologist at St. Jude Children's Research Hospital. "We never thought we would actually identify this molecule to be important in influenza viral infection, because there is no DNA stage in the influenza life cycle. ZBP1 does an amazing job of killing off infected cells. But it would be very useful to modulate ZBP1 in later stages of the infection, when the uncontrolled inflammation causes damage."
"Since the pathology that we saw in the mice matches what is seen in humans, we will now explore translating these findings to humans," said Dr. Kanneganti. "If we can somehow modulate the activation of this pathway, that will help to decrease the exaggerated inflammatory response that causes mortality during influenza infection. We have shown that these molecules are important in viral infections, but now we want to test their role in other inflammatory conditions. ZBP1 is likely not dedicated to attacking only the influenza virus. Maybe it also plays other roles, and if we fully understand those roles, we can learn how to manipulate immune responses."
Related Links:
St. Jude Children's Research Hospital
Individuals infected with influenza become ill not only because of the presence of virus but also because of the inflammatory immune response triggered by reaction to the virus.
The Z-DNA binding protein 1 (ZBP1, also known as DNA-dependent activator of IFN regulatory factors) gene encodes a Z-DNA binding protein. Z-DNA formation is a dynamic process, largely controlled by the amount of supercoiling. ZBP1 recognizes DNA in the cytoplasm as an antiviral mechanism. Viral life cycles often include steps where DNA is exposed in the cytoplasm. DNA is normally contained in the nucleus of a cell, and therefore cells use proteins like ZBP1 as an indicator of a viral infection. Once ZBP1 is activated, it increases the production of antiviral cytokines such as interferon-beta (INF-beta).
Investigators at St. Jude Children's Research Hospital (Memphis, TN, USA) initially demonstrated that ZBP1-mediated sensing of the influenza A virus (IAV) proteins NP and PB1 triggered cell death and inflammatory responses.
In order to further clarify the role of ZPB1 in flu infection, they used genetic engineering techniques to create a line of mice that lacked the ZBP1 gene.
The investigators reported in the August 12, 2016, online edition of the journal Science Immunology that mice lacking ZBP1 showed an increased viral load and delayed recovery. On the other hand, these mice had decreased inflammation and less epithelial damage than control animals.
"Our discovery was totally unexpected," said senior author Dr. Thirumala-Devi Kanneganti, an immunologist at St. Jude Children's Research Hospital. "We never thought we would actually identify this molecule to be important in influenza viral infection, because there is no DNA stage in the influenza life cycle. ZBP1 does an amazing job of killing off infected cells. But it would be very useful to modulate ZBP1 in later stages of the infection, when the uncontrolled inflammation causes damage."
"Since the pathology that we saw in the mice matches what is seen in humans, we will now explore translating these findings to humans," said Dr. Kanneganti. "If we can somehow modulate the activation of this pathway, that will help to decrease the exaggerated inflammatory response that causes mortality during influenza infection. We have shown that these molecules are important in viral infections, but now we want to test their role in other inflammatory conditions. ZBP1 is likely not dedicated to attacking only the influenza virus. Maybe it also plays other roles, and if we fully understand those roles, we can learn how to manipulate immune responses."
Related Links:
St. Jude Children's Research Hospital
Latest BioResearch News
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Blood Test Reveals Hidden Pancreatic Cancer After Treatment
Pancreatic cancer often returns even after chemotherapy and surgery, while microscopic disease can remain difficult to detect during surveillance. Standard imaging and broad-panel liquid biopsy tests may... Read more
Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that rapidly impairs motor function and shortens survival, creating sustained demand for multidisciplinary care.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








